Overexpression of CARM1 in breast cancer is correlated with poorly characterized clinicopathologic parameters and molecular subtypes

详细信息    查看全文

• 作者：Hongxia Cheng (1) (2)
  Yejun Qin (2)
  Hui Fan (2)
  Peng Su (1)
  Xiaofang Zhang (1)
  Hui Zhang (1)
  Gengyin Zhou (1)
  
• 关键词：CARM1 ; Breast cancer ; Clinicopathologic parameters ; HER2 ; Molecular subtype
• 刊名：Diagnostic Pathology
• 出版年：2013
• 出版时间：December 2013
• 年：2013
• 卷：8
• 期：1
• 全文大小：326KB
• 参考文献：1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. / Int J Cancer 2010, 127:2893鈥?917. CrossRef
  2. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF: American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. / J Clin Oncol 2007, 25:118鈥?45. CrossRef
  3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. / Science 1987, 235:177鈥?82. CrossRef
  4. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN: The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. / Oncologist 2009, 14:320鈥?68. CrossRef
  5. Baselga J, Swain SM: Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. / Nat Rev Cancer 2009, 9:463鈥?75. CrossRef
  6. Wong ST, Goodin S: Overcoming drug resistance in patients with metastatic breast cancer. / Pharmacotherapy 2009, 29:954鈥?65. CrossRef
  7. Bedford MT, Clarke SG: Protein arginine methylation in mammals: who, what, and why. / Mol Cell 2009, 33:1鈥?3. CrossRef
  8. Chen D, Ma H, Hong H, Koh SS, Huang SM, Schurter BT, Aswad DW, Stallcup MR: Regulation of transcription by a protein methyltransferase. / Science 1999, 284:2174鈥?177. CrossRef
  9. Ma H, Baumann CT, Li H, Strahl BD, Rice R, Jelinek MA, Aswad DW, Allis CD, Hager GL, Stallcup MR: Hormone-dependent, CARM1-directed, arginine-specific methylation of histone H3 on a steroid-regulated promoter. / Curr Biol 2001, 11:1981鈥?985. CrossRef
  10. Daujat S, Bauer UM, Shah V, Turner B, Berger S, Kouzarides T: Crosstalk between CARM1 methylation and CBP acetylation on histone H3. / Curr Biol 2002, 12:2090鈥?097. CrossRef
  11. Ceschin DG, Walia M, Wenk SS, Duboe C, Gaudon C, Xiao Y, Fauquier L, Sankar M, Vandel L, Gronemeyer H: Methylation specifies distinct estrogen-induced binding site repertoires of CBP to chromatin. / Genes Dev 2011, 25:1132鈥?146. CrossRef
  12. Ali S, Coombes RC: Endocrine-responsive breast cancer and strategies for combating resistance. / Nat Rev Cancer 2002, 2:101鈥?12. CrossRef
  13. Al-Dhaheri M, Wu J, Skliris GP, Li J, Higashimato K, Wang Y, White KP, Lambert P, Zhu Y, Murphy L, Xu W: CARM1 is an important determinant of ERalpha-dependent breast cancer cell differentiation and proliferation in breast cancer cells. / Cancer Res 2011, 71:2118鈥?128. CrossRef
  14. Urwyler O, Zhang L, Li X, Imboden H, Suter B: Tissue-dependent subcellular localization of Drosophila arginine methyl-transferase 4 (DART4), a coactivator whose overexpression affects neither viability nor differentiation. / Differentiation 2007, 75:757鈥?65. CrossRef
  15. Frietze S, Lupien M, Silver PA, Brown M: CARM1 regulates estrogen-stimulated breast cancer growth through up-regulation of E2F1. / Cancer Res 2008, 68:301鈥?06. CrossRef
  16. El MS, Fabbrizio E, Rodriguez C, Chuchana P, Fauquier L, Cheng D, Theillet C, Vandel L, Bedford MT, Sardet C: Coactivator-associated arginine methyltransferase 1 (CARM1) is a positive regulator of the cyclin E1 gene. / Proc Natl Acad Sci USA 2006, 103:13351鈥?3356. CrossRef
  17. Kim YR, Lee BK, Park RY, Nguyen NT, Bae JA, Kwon DD, Jung C: Differential CARM1 expression in prostate and colorectal cancers. / BMC Cancer 2010, 10:197. CrossRef
  18. Majumder S, Liu Y, Ford OH 3rd, Mohler JL, Whang YE: Involvement of arginine methyltransferase CARM1 in androgen receptor function and prostate cancer cell viability. / Prostate 2006, 66:1292鈥?301. CrossRef
  19. Hong H, Kao C, Jeng MH, Eble JN, Koch MO, Gardner TA, Zhang S, Li L, Pan CX, Hu Z, MacLennan GT, Cheng L: Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status. / Cancer 2004, 101:83鈥?9. CrossRef
  20. Lakhani SR, Ellis IO, Schnitt SJ, Puay Hoon T, Marc J, Van De V: / WHO Classification of Tumours of the Breast. Lyon: International Agency for Research on Cancer (IARC) Press; 2012.
  21. Edge SB, Byrd DR (Eds): / AJCC Cancer Staging Manual. 7th edition. New York: Springer; 2010.
  22. Kim RG, Kim EK, Kim HA, Koh JS, Kim MS, Kim KI, Lee JI, Moon NM, Ko E, Noh WC: Prognostic significance of molecular subtype in T1N0M0 breast cancer: Korean experience. / Eur J Surg Oncol 2011, 37:629鈥?34. CrossRef
  23. Skliris GP, Leygue E, Curtis-Snell L, Watson PH, Murphy LC, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC: Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours. / Br J Cancer 2006, 95:616鈥?26. CrossRef
  24. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC: Race, breast cancer subtypes, and survival in the Carolina breast cancer study. / JAMA 2006, 295:2492鈥?502. CrossRef
  25. Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, Hewitt SM, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, Zatonski W, Cartun R, Mandich D, Rymkiewicz G, Ligaj M, Lukaszek S, Kordek R, Garcia-Closas M: Differences in risk factors for breast cancer molecular subtypes in a population-based study. / Cancer Epidemiol Biomarkers Prev 2007, 16:439鈥?43. CrossRef
  26. Collins LC, Marotti JD, Gelber S, Cole K, Ruddy K, Kereakoglow S, Brachtel EF, Schapira L, Come SE, Winer EP, Partridge AH: Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. / Breast Cancer Res Treat 2012, 131:1061鈥?066. CrossRef
  27. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. / Proc Natl Acad Sci U S A 2001, 98:10869鈥?0874. CrossRef
  28. Qin X, Peng Q, Qin A, Chen Z, Lin L, Deng Y, Xie L, Xu J, Li H, Li T, Li S, Zhao J: Association of COMT Val158Met polymorphism and breast cancer risk: an updated meta-analysis. / Diagn Pathol 2012, 7:136. CrossRef
  29. El FH, Chahbouni S, Jayi S, Moumna K, Melhouf MA, Bannani A, Mesbahi O, Amarti A: Luminal B tumors are the most frequent molecular subtype in breast cancer of North African women: an immunohistochemical profile study from Morocco. / Diagn Pathol 2012, 7:170. CrossRef
  30. Zhang Q, Zhang Q, Cong H, Zhang X: The ectopic expression of BRCA1 is associated with genesis, progression, and prognosis of breast cancer in young patients. / Diagn Pathol 2012, 7:181. CrossRef
  31. Jones HA, Antonini N, Hart AA, Peterse JL, Horiot JC, Collin F, Poortmans PM, Oei SB, Collette L, Struikmans H, Van den Bogaert WF, Fourquet A, Jager JJ, Schinagl DA, Warlam-Rodenhuis CC, Bartelink H: Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial. / J Clin Oncol 2009, 27:4939鈥?947. CrossRef
  32. Van der Hage JA, Mieog JS, van de Velde CJ, Putter H, Bartelink H, van de Vijver MJ: Impact of established prognostic factors and molecular subtype in very young breast cancer patients: pooled analysis of four EORTC randomized controlled trials. / Breast Cancer Res 2011, 13:R68. CrossRef
  33. Wu Q, Bruce AW, Jedrusik A, Ellis PD, Andrews RM, Langford CF, Glover DM, Zernicka-Goetz M: CARM1 is required in embryonic stem cells to maintain pluripotency and resist differentiation. / Stem Cells 2009, 27:2637鈥?645. CrossRef
  34. Feng Q, He B, Jung SY, Song Y, Qin J, Tsai SY, Tsai MJ, O'Malley BW: Biochemical control of CARM1 enzymatic activity by phosphorylation. / J Biol Chem 2009, 284:36167鈥?6174. CrossRef
  35. Yadav N, Lee J, Kim J, Shen J, Hu MC, Aldaz CM, Bedford MT: Specific protein methylation defects and gene expression perturbations in coactivator-associated arginine methyltransferase 1-deficient mice. / Proc Natl Acad Sci U S A 2003, 100:6464鈥?468. CrossRef
  36. Lupien M, Eeckhoute J, Meyer CA, Krum SA, Rhodes DR, Liu XS, Brown M: Coactivator function defines the active estrogen receptor alpha cistrome. / Mol Cell Biol 2009, 29:3413鈥?423. CrossRef
  37. Carascossa S, Dudek P, Cenni B, Briand PA, Picard D: CARM1 mediates the ligand-independent and tamoxifen-resistant activation of the estrogen receptor alpha by cAMP. / Genes Dev 2010, 24:708鈥?19. CrossRef
  38. Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A, Revil C, Jones A: Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. / J Clin Oncol 2009, 27:5529鈥?537. CrossRef
  39. Higgins MJ, Baselga J: Targeted therapies for breast cancer. / J Clin Invest 2011, 121:3797鈥?803. CrossRef
  40. Feng Q, Yi P, Wong J, O'Malley BW: Signaling within a coactivator complex: methylation of SRC-3/AIB1 is a molecular switch for complex disassembly. / Mol Cell Biol 2006, 26:7846鈥?857. CrossRef
  41. Lahusen T, Henke RT, Kagan BL, Wellstein A, Riegel AT: The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer. / Breast Cancer Res Treat 2009, 116:225鈥?37. CrossRef
  42. Kim D, Lee J, Cheng D, Li J, Carter C, Richie E, Bedford MT: Enzymatic activity is required for the in vivo functions of CARM1. / J Biol Chem 2010, 285:1147鈥?152. CrossRef
  
• 作者单位：Hongxia Cheng (1) (2)
  Yejun Qin (2)
  Hui Fan (2)
  Peng Su (1)
  Xiaofang Zhang (1)
  Hui Zhang (1)
  Gengyin Zhou (1)
  
  1. Department of Pathology, Shandong University School of Medicine, 44#, Wenhua Xi Road, Jinan, Shandong, 250012, People鈥檚 Republic of China
  2. Department of Pathology, Provincial Hospital Affiliated to Shandong University, 324#, Jing 5 Rd, Jinan, Shandong, 250021, People鈥檚 Republic of China
  

文摘

Background Coactivator-associated arginine methyltransferase 1 (CARM1) belongs to the protein arginine methyltransferase family. CARM1 has been reported to be associated with high grade tumors in breast cancer. It still remains unknown the expression pattern of CARM1 in breast cancer and its relationships with clinicopathological characteristics and molecular subtypes. Methods Two hundred forty-seven invasive breast cancer cases were collected and prepared for tissue array. There were thirty-seven tumors with benign glandular epithelium adjacent to the tumors among these cases. Molecular subtype and CARM1 expression were investigated using immunohistochemistry. Results Cell staining was observed in the cytoplasm and/or nucleus. Staining for CARM1 was significantly stronger in adenocarcinoma compared with adjacent benign epithelium. There is a significant correlation between CARM1 overexpression with young age, high grade, estrogen receptor (ER) and progesterone receptor (PR) negative, increased p53 expression, and high Ki-67 index. Our study demonstrated CARM1 overexpression was associated with an increase in the protein expression of HER2. Furthermore, our data indicated CARM1-overexpression rate were remarkably higher in HER2 subtype (69.6%), luminal B subtype (59.6%) and TN subtype (57.1%) compared with luminal A subtype (41.3%). Conclusions CARM1 expression was increased in invasive breast cancer. CARM1 overexpression was associated with poorly characterized clinicopathologic parameters and HER2 overexpression. There were significant differences between different molecular subtypes in their relationship to CARM1 overexpression. Our results support the value of using CARM1 in prognostic stratification of breast cancer patients and its potential therapeutic implications in targeting treatment. Virtual slides The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/4116338491022965